Canadian Obesity Network publishes first-ever Report Card On Access to Obesity Treatment For Adults in Canada 2017
A paradigm shift in the prevention and treatment of obesity.
The report is a shift away from considering obesity to be merely the result of poor lifestyle choices toward a socio-ecological model of health that carries with it an obligation to our health systems and society to prevent and treat it as we do other chronic diseases.
Understanding your Body Mass Index (BMI)
Health Canada’s Canadian Guidelines for Body Weight Classification in Adults uses the Body Mass Index (BMI) to determine if someone is overweight. You can calculate your BMI using the formula below or online here:
BMI = weight (kg)/height (m)2
Health Canada’s Health Risk Classification According to Body Mass Index (BMI) table shows the correlation between your BMI score and your risk of developing health problems, such as type 2 diabetes, high blood pressure, heart disease, stroke, arthritis and cancer. Please note other factors may influence your BMI. You should consult your family physician if you are concerned about being overweight.
Image courtesy of yodiyim at FreeDigitalPhotos.net
According to a study published in Osteoarthritis and Cartilage, the rate of osteoarthritis (OA) is increasing and Canada’s aging population and rising rate of obesity is to blame. Osteoarthritis is a leading cause of chronic pain and loss of mobility in Canada and is associated with reduced productivity and increased burden on the health care system.
Statistics Canada reports that almost two-thirds of Canadian adults and 23% of children are overweight or obese. “These compelling demographic trends will increase the burden of OA and the associated disability among the working age population will become substantial in the coming years,” Behram Sharif, research team lead and an Alberta Bone and Joint Health Institute post-doctoral fellow based at the University of Calgary, said. Continue reading
A recent study published in the journal Arthritis & Rheumatology concluded that disease-modifying anti rheumatic drugs (DMARDs) may influence rheumatoid arthritis (RA) patients’ weight. The study looked at four DMARDs, including methotrexate, leflunomide, prednisone and tutor necrosis factor inhibitors (TNFis).
Researcher Joshua F. Baker and his team at the Philadelphia VA Medical Centre in Pennsylvania assessed how primary RA therapies influence changes in body mass index (BMI). A low BMI is one of the adverse long-term outcome in RA and disease-related weight loss may be the result of RA symptoms or treatment therapy.
The team used three large administrative databases to identify 32,859 RA patients who received treatment with methotrexate, leflunomide, prednisone and TNFis. Researchers also assessed independent factors that may affect the study outcome, including the patient’s age, sex, race, BMI, seropositivity* for anticyclic citrullinated peptides (CCP), diabetes, current smoking habits, comorbidities, C-reactive protein (CRP) levels, interstitial or other lung disease, malignancies, history of myocardial infarction, chronic kidney disease, and other factors.
Here are the findings from the study: Continue reading